-
Je něco špatně v tomto záznamu ?
Phage therapy of antibiotic-resistant strains of Klebsiella pneumoniae, opportunities and challenges from the past to the future
M. Mohammadi, M. Saffari, SD. Siadat
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
3150
Kashan University of Medical Sciences
Odkazy
PubMed
37036571
DOI
10.1007/s12223-023-01046-y
Knihovny.cz E-zdroje
- MeSH
- antibakteriální látky MeSH
- bakteriofágy * MeSH
- fágová terapie * MeSH
- infekce bakteriemi rodu Klebsiella * mikrobiologie MeSH
- Klebsiella pneumoniae MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Klebsiella spp. is a commensal gram-negative bacterium and a member of the human microbiota. It is the leading cause of various hospital-acquired infections. The occurrence of multi-drug drug resistance and carbapenemase-producing strains of Klebsiella pneumoniae producing weighty contaminations is growing, and Klebsiella oxytoca is an arising bacterium. Alternative approaches to tackle contaminations led by these microorganisms are necessary as strains enhance opposing to last-stage antibiotics in the way that Colistin. The lytic bacteriophages are viruses that infect and rapidly eradicate bacterial cells and are strain-specific to their hosts. They and their proteins are immediately deliberate as opportunities or adjuncts to antibiotic therapy. There are several reports in vitro and in vivo form that proved the potential use of lytic phages to combat superbug stains of K. pneumoniae. Various reports dedicated that the phage area can be returned to the elimination of multi-drug resistance and carbapenemase resistance isolates of K. pneumoniae. This review compiles our current information on phages of Klebsiella spp. and highlights technological and biological issues related to the evolution of phage-based therapies targeting these bacterial hosts.
Microbiology Research Center Pasteur Institute of Iran Tehran Iran
Tuberculosis and Pulmonary Research Department Pasteur Institute of Iran Tehran Iran
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23008923
- 003
- CZ-PrNML
- 005
- 20230707093247.0
- 007
- ta
- 008
- 230707s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-023-01046-y $2 doi
- 035 __
- $a (PubMed)37036571
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Mohammadi, Mehrdad $u Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran. mehrdad.mohammadi1984@gmail.com $1 https://orcid.org/0000000218655238
- 245 10
- $a Phage therapy of antibiotic-resistant strains of Klebsiella pneumoniae, opportunities and challenges from the past to the future / $c M. Mohammadi, M. Saffari, SD. Siadat
- 520 9_
- $a Klebsiella spp. is a commensal gram-negative bacterium and a member of the human microbiota. It is the leading cause of various hospital-acquired infections. The occurrence of multi-drug drug resistance and carbapenemase-producing strains of Klebsiella pneumoniae producing weighty contaminations is growing, and Klebsiella oxytoca is an arising bacterium. Alternative approaches to tackle contaminations led by these microorganisms are necessary as strains enhance opposing to last-stage antibiotics in the way that Colistin. The lytic bacteriophages are viruses that infect and rapidly eradicate bacterial cells and are strain-specific to their hosts. They and their proteins are immediately deliberate as opportunities or adjuncts to antibiotic therapy. There are several reports in vitro and in vivo form that proved the potential use of lytic phages to combat superbug stains of K. pneumoniae. Various reports dedicated that the phage area can be returned to the elimination of multi-drug resistance and carbapenemase resistance isolates of K. pneumoniae. This review compiles our current information on phages of Klebsiella spp. and highlights technological and biological issues related to the evolution of phage-based therapies targeting these bacterial hosts.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Klebsiella pneumoniae $7 D007711
- 650 _2
- $a antibakteriální látky $7 D000900
- 650 12
- $a fágová terapie $7 D000071059
- 650 12
- $a bakteriofágy $7 D001435
- 650 12
- $a infekce bakteriemi rodu Klebsiella $x mikrobiologie $7 D007710
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Saffari, Mahmood $u Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
- 700 1_
- $a Siadat, Seyed Davar $u Tuberculosis and Pulmonary Research Department, Pasteur Institute of Iran, Tehran, Iran $u Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 68, č. 3 (2023), s. 357-368
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37036571 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230707 $b ABA008
- 991 __
- $a 20230707093241 $b ABA008
- 999 __
- $a ok $b bmc $g 1954415 $s 1195186
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 68 $c 3 $d 357-368 $e 20230410 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
- GRA __
- $a 3150 $p Kashan University of Medical Sciences
- LZP __
- $a Pubmed-20230707